BR112015020179A2 - piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onas - Google Patents
piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onasInfo
- Publication number
- BR112015020179A2 BR112015020179A2 BR112015020179A BR112015020179A BR112015020179A2 BR 112015020179 A2 BR112015020179 A2 BR 112015020179A2 BR 112015020179 A BR112015020179 A BR 112015020179A BR 112015020179 A BR112015020179 A BR 112015020179A BR 112015020179 A2 BR112015020179 A2 BR 112015020179A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- indol
- disease
- diazepino
- piperazine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
Abstract
resumo patente de invenção: "piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onas". a presente invenção refere-se aos compostos de fórmula geral i i em que r1, r2, r3 e x são como definidos no relatório descritivo, ou a um sal de adição de ácido farmaceuticamente aceitável, a uma mistura racêmica ou ao seu enantiômero correspondente e/ou isômeros óticos dos mesmos para uso como substâncias ativas terapêuticas no tratamento de esquizofrenia, distúrbio de personalidade obsessivo-compulsivo, depressão maior, distúrbios bipolares, distúrbios de ansiedade, envelhecimento normal, epilepsia, degeneração retinal, lesão cerebral traumática, lesão da medula espinhal, transtorno de estresse pós-traumático, transtorno do pânico, doença de parkinson, demência, doença de alzheimer, comprometimento cognitivo, disfunção cognitiva induzida por quimioterapia, síndrome de down, transtornos do espectro autista, perda de audição, zumbido, ataxia espinocerebelar, esclerose lateral amiotrófica, esclerose múltipla, doença de huntington, acidente vascular cerebral, terapia de radiação, estresse crônico, abuso de fármaco neuroativo, tais como álcool, opiatos, metanfetamina, fenciclidina e cocaína, bem como refere-se a seu processo de fabricação, sua composição farmacêutica e seu uso no preparo de um medicamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13161949 | 2013-04-02 | ||
PCT/EP2014/056393 WO2014161801A1 (en) | 2013-04-02 | 2014-03-31 | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015020179A2 true BR112015020179A2 (pt) | 2017-07-18 |
Family
ID=47997284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015020179A BR112015020179A2 (pt) | 2013-04-02 | 2014-03-31 | piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onas |
Country Status (13)
Country | Link |
---|---|
US (1) | US9586966B2 (pt) |
EP (1) | EP2981538B1 (pt) |
JP (1) | JP6212623B2 (pt) |
KR (1) | KR101767329B1 (pt) |
CN (1) | CN105246895B (pt) |
AR (1) | AR095970A1 (pt) |
BR (1) | BR112015020179A2 (pt) |
CA (1) | CA2905270C (pt) |
HK (1) | HK1213553A1 (pt) |
MX (1) | MX2015013915A (pt) |
RU (1) | RU2628126C2 (pt) |
TW (1) | TW201443056A (pt) |
WO (1) | WO2014161801A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20150341A1 (es) * | 2012-08-06 | 2015-02-28 | Hoffmann La Roche | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3867374A (en) * | 1968-06-05 | 1975-02-18 | Mcneilab Inc | Diazepinoindoles |
JPS4927198B1 (pt) * | 1968-06-05 | 1974-07-16 | ||
US3689503A (en) * | 1970-07-30 | 1972-09-05 | Mcneilab Inc | Indole-2-carboxylates |
GB0106177D0 (en) * | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
WO2007065820A1 (en) * | 2005-12-09 | 2007-06-14 | F. Hoffmann-La Roche Ag | Tricyclic amide derivatives useful for treating obesity |
WO2008046072A2 (en) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
US20090192147A1 (en) * | 2008-01-30 | 2009-07-30 | Wyeth | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
WO2012006419A2 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
RU2472795C1 (ru) * | 2011-05-20 | 2013-01-20 | Федеральное государственное бюджетное учреждение " Научно-исследовательский институт фармакологии имени В.В. Закусова Российской академии медицинских наук | 2-ЗАМЕЩЕННЫЕ-1,2,4,5-ТЕТРАГИДРО-3H-ПИРРОЛО[1,2-a][1,4]ДИАЗЕПИН-3-ОНЫ |
PE20150341A1 (es) * | 2012-08-06 | 2015-02-28 | Hoffmann La Roche | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona |
-
2014
- 2014-03-31 EP EP14717110.2A patent/EP2981538B1/en active Active
- 2014-03-31 BR BR112015020179A patent/BR112015020179A2/pt not_active Application Discontinuation
- 2014-03-31 CN CN201480019506.5A patent/CN105246895B/zh active Active
- 2014-03-31 RU RU2015144197A patent/RU2628126C2/ru not_active IP Right Cessation
- 2014-03-31 WO PCT/EP2014/056393 patent/WO2014161801A1/en active Application Filing
- 2014-03-31 CA CA2905270A patent/CA2905270C/en not_active Expired - Fee Related
- 2014-03-31 TW TW103111999A patent/TW201443056A/zh unknown
- 2014-03-31 MX MX2015013915A patent/MX2015013915A/es unknown
- 2014-03-31 KR KR1020157026876A patent/KR101767329B1/ko active IP Right Grant
- 2014-03-31 JP JP2016505780A patent/JP6212623B2/ja active Active
- 2014-04-01 AR ARP140101448A patent/AR095970A1/es unknown
-
2015
- 2015-09-28 US US14/868,059 patent/US9586966B2/en active Active
-
2016
- 2016-02-11 HK HK16101473.6A patent/HK1213553A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP6212623B2 (ja) | 2017-10-11 |
CA2905270C (en) | 2017-09-05 |
KR20150122234A (ko) | 2015-10-30 |
AR095970A1 (es) | 2015-11-25 |
EP2981538B1 (en) | 2017-08-02 |
MX2015013915A (es) | 2015-12-11 |
CA2905270A1 (en) | 2014-10-09 |
US20160016963A1 (en) | 2016-01-21 |
EP2981538A1 (en) | 2016-02-10 |
TW201443056A (zh) | 2014-11-16 |
KR101767329B1 (ko) | 2017-08-10 |
CN105246895B (zh) | 2017-09-22 |
RU2015144197A (ru) | 2017-05-04 |
HK1213553A1 (zh) | 2016-07-08 |
RU2628126C2 (ru) | 2017-08-15 |
JP2016515593A (ja) | 2016-05-30 |
CN105246895A (zh) | 2016-01-13 |
US9586966B2 (en) | 2017-03-07 |
WO2014161801A1 (en) | 2014-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015004942A2 (pt) | benzimidazóis como agentes ativos do snc | |
BR112015011094A2 (pt) | 1,6-naftiridinas substituídas | |
BR112017022568A2 (pt) | compostos e seus usos como inibidores de bace1 | |
ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
JP2010502722A5 (pt) | ||
RU2012140148A (ru) | (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения | |
MX362532B (es) | Derivados de 1,7-naftiridina. | |
AR093576A1 (es) | Derivados heterociclicos sustituidos | |
BR112015027362A8 (pt) | derivados de isoquinolina estimulantes de neurogênese | |
BR112015030597A2 (pt) | derivados 4-amino-6-fenil-6,7-di-hidro[1,2,3]triazolo[1,5-a]pirazina como inibidores de beta-secretase (bace) | |
BR112015030678A2 (pt) | derivados 4-amino-6-fenil-5,6-di-hidroimidazo [1,5-a] pirazina como inibidores de beta-secretase (bace) | |
CA2864606C (en) | Methods of treating and preventing diseases and disorders of the central nervous system | |
AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion | |
CL2007002768A1 (es) | Compuestos derivados de quinolin-amina; proceso de preparacion de dichos compuestos; medicamento; y uso para el tratamiento de enfermedades tales como depresion, trastornos de ansiedad, esquizofrenia, agorafobia, dolor, demencia y enfermedad de parki | |
BR112015020179A2 (pt) | piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-onas | |
BR112015000313A2 (pt) | piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona | |
PH12016500605A1 (en) | Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
BR112015008200A2 (pt) | derivados de imidazopiridina | |
RU2016132574A (ru) | Органические соединения | |
WO2012038850A8 (en) | Pyrimidones for treatment of potassium channel related diseases | |
ITRM20050447A1 (it) | Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson. | |
GT200900150A (es) | Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen. | |
ECSP084767A (es) | Pirazolopirimidinas y tiazolopirimidinas sustituidas | |
BR112015001218A2 (pt) | moduladores de benzisoxazol de neurogênese | |
BRPI0417797A (pt) | soro sangüìneo biologicamente ativo, métodos para produzi-lo e seus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |